1. Don't Get Mad. Get GladwellAnother week, another reason to make fun of nanotechnology. See, we're still trying to get excited about the investment opportunities of nanotech, roughly defined as the science of tiny little stuff. We're sure that lots of scientists are doing cool things for real companies in the nanotech field. But we can't help noticing that everyone who's boosting nanotech as an investment idea these days feels compelled to make preposterous claims on its behalf -- weirdly optimistic futurology such as "Nanotech will enable us to reduce the Library of Congress to the size of a Jujyfruit." As if that were a pressing need. Anyway, the whole nanotech movement -- as respectable as it may be one day -- can't move a molecule without sounding like some sort of elaborate investment scam. Our latest case in point: this week's NanoBusiness News from the NanoBusiness Development Group consultants. In an interview with nanotech VC Josh Wolfe -- an editor of a nanotech newsletter published by Forbes -- we didn't get halfway into the Q&A before the expression "tipping point" creeped into the dialogue three times. Aieeeee! Tipping point! Will no one save us from the tipping point?
|No Gratuities, Please |
Tipping point's breaking point
|*2003 figures are estimates based on mentions through 6/5/2003.**Articles mentioning tipping point but not Malcolm Gladwell.Source: Factiva|
We at the Five Dumbest Things Research Lab are aware that one Malcolm Gladwell has written some thoughtful book called
2. The Customer Is Always
|At Your Service |
David Dorman goes low-tech
3. Cerus Your Old ManWhat hath Eliot Spitzer wrought? We gueth we'll find out thoon. As ace biotech reporter Adam Feuerstein pointed out, the blood-focused Cerus ( CERS) commenced a public offering of 6 million shares Thursday, a day after the company announced the latest delay in getting its flagship product to market. What most fascinated us about the news was Feuerstein's observation regarding underwriter Morgan Stanley. See, Glenn Reicin, the Morgan Stanley analyst who covers Cerus, has an underweight-volatile rating on the stock -- a ranking he reiterated Wednesday, given "the projected length of time to profitability, the company's projected financing needs and the challenges the company faces in achieving its operating targets." This, of course, is exactly what you want in the New Wall Street: research analysts not bothering to coordinate their stock ratings with their firms' investment banking business. But we at the research lab are thankful we're not a Morgan Stanley broker trying to hawk this particular issue. We can imagine what it's like to be working the phones for this one. "Cerus, huh? Never heard of it," says the investor at the other end of the line. "What does your research guy think of it?" "Um, um. ... You know, I forgot to ask," replies the broker. "What do you say I get back to you on that one?"
4. Yes, I Am Wise. But It's Wisdom Born of Exercise PricesHere's something fascinating we learned this week: Stock options are a women's issue. At least, that's what Sen. Barbara Boxer (D., Calif.) believes.
|For Women Only |
Barbara Boxer's take on options